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Summary
Context. — Although thrombolysis (THL) and primary percutaneous coronary intervention (PPCI)
are two validated options in reperfusion algorithms for ST-elevation myocardial infarction
(STEMI), recent papers seems to show that PPCI could be the best therapeutic option
irrespective of the time to treatment (TT) and of the cardiovascular risk profile of the patient.
The impact of TT and age on reperfusion strategies requires elucidation. The aim of this study
was to analyze the effect of time to treatment and age on the 1-year mortality of patients
presenting with STEMI, for each reperfusion strategy. 
Materials and methods. — The study population consisted in 794 patients directly admitted to
the cardiological intensive care unit for STEMI ≤ 12 hours. The relationship between TT and
1-year mortality was studied using logistic regression models. The models were implemented
on the overall population and on 3 different age groups: [<65 years]; [≥65 and <75 years];
[≥ 75 years] for patients undergoing THL (n=299) and for patients undergoing PPCI (n = 495).
There was no significant between-group difference in all-cause 1-year mortality for the patients
[< 65 years] and those [≥ 65 and < 75 years]. In contrast, the 1-year mortality was significantly
higher in the patients [≥ 75 years] undergoing THL (51.4 vs. 15.3%; p<0.001). The analysis of the
curves of mortality suggests that 1- year mortality of patients with STEMI depend not only on
reperfusion strategy but so on the time to treatment and on the age of the patients.
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Conclusion. — In STEMI, on a 1-year mortality criteria, PPCI is not always upper than THL,
particularly for patients < 65 years treated within the first two hours after symptoms onset. TT
and age affects the results of the reperfusion strategies and must be still incorporated in the
reperfusion algorithms of STEMI.
© 2008 Published by Elsevier Masson SAS.
Résumé
Contexte. — Bien que le délai de traitement soit le paramètre majeur des algorithmes de
revascularisation dans les STEMI, son rôle pourrait dépendre du type de revascularisation et du
profil de risque cardio vasculaire et plus particulièrement de l’âge des patients. Son impact
dans les stratégies de revascularisation nécessite d’être clarifié. Le but de notre travail était
d’analyser par classe d’âge, pour chaque stratégie de revascularisation, l’effet du délai de
traitement sur la mortalité à un an des patients avec STEMI.
Matériels et méthodes. — La population de l’étude était constituée de 794 patients admis
directement en USIC pour un STEMI ≤ 12 heures. La relation entre le délai de traitement et la
mortalité à un an a été étudiée par des modèles de régression logistique. Ces modèles ont été
réalisés dans la population générale et dans les 3 sous groupes d’âge différent: [< 65 ans] ; [≥
65 et < 75 ans] ; [≥ 75 ans] pour les patients traités par thrombolyse (n = 299) et pour les
patients traités par angioplastie primaire (n=495). La mortalité à un an toute cause n’était pas
significativement différente entre le deux groupes de traitement pour les patients [< 65 ans] et
pour ceux du groupe [≥ 65 et < 75 ans]. En revanche, la mortalité à un an était significativement
plus importante dans le groupe de patients [≥ 75 ans] traités par thrombolyse (51,4 % versus
15,3 %; p <0.001). L’analyse des courbes de décès en fonction du délai de traitement montre
que l’effet du délai de traitement sur la mortalité à un an dépends de la stratégie de
revascularisation et de l’âge des patients. 
Conclusion. — Nos résultats suggèrent que le délai de traitement affecte la mortalité de façon
variable selon la stratégie de revascularisation utilisée et l’âge des patients traités. Ainsi, l’âge
devrait faire partie des algorithmes en phase aigue de STEMI.
© 2008 Published by Elsevier Masson SAS.
Introduction
Various recommendations advise using primary percutaneous
coronary intervention (PPCI) for all patients with ST-elevation
myocardial infarction (STEMI) ≤12 hours when PPCI can be
conducted within 90 minutes of the initial medical contact. In
other cases, trombolysis (THL), particularly pre-hospital THL,
is to be preferred in the absence of contra-indication. In other
respects, age is not clearly included in these algorithms pro-
posed in these recommendations (1-3). Recently, a large-scale
study including pre-hospital THL have demonstrated that PPCI
may be superior to THL irrespective of the time to treatment
(TT) and of the age of the patients (4) whereas another one
showed that reperfusion algorithm could also depend on
patient age, on the TT and on STEMI topography (5). Thus, the
impact of time to treatment and age on reperfusion stra-
tegies requires elucidation. The aim of this study was to
analyze the effect of time to treatment and age on 1-year
mortality in patients presenting with STEMI, for each reperfu-
sion strategy.
Materials and methods
Population
The data were derived from a single-center, prospective,
exhaustive STEMI registry. In order to define the study
population, 1648 admissions for STEMI ≤ 12 h between 1995
and 2005 were analyzed. All the patients included in the
study had, on an ECG recording, in at least 2 contiguous
leads, an ST-segment elevation ≥ 1 mm in the bipolar leads
or ≥ 2 mm in the precordial leads. In order to prevent bias,
patients transferred from other centers were excluded due
to the very variable time intervals between THL administra-
tion and rescue PCI implementation (n = 508). Similarly,
patients presenting with cardiogenic shock on admission
were excluded since PPCI is known to be superior to THL
(n = 37). Patients who did not undergo reperfusion therapy
in the acute phase due to a non-contributive ECG or
because they were considered too frail for that therapy
were also excluded (n = 269). Forty patients were lost to
follow-up (n = 40). In all, 794 patients were included in the
analysis (figure 1). All the patients received aspirin, heparin
and clopidogrel in the absence of any contra-indication. In
the THL group, various thrombolytics were used: streptoki-
nase, alteplase and tenecteplase. If THL efficacy was not
patent at 90 min (persistent pain or non-resolution of ST-
segment elevation), angiographic control was performed
and rescue PCI implemented if the TIMI flow was < 3. In
other cases, the patient underwent coronary angiography
after a few days and was reperfused according to the
ischemia test data. PPCI was considered as successful when
a TIMI 3 flow grade and a less than 30 per cent residual ste-
nosis was obtained. In these patients abciximab was used
since 2000. Only the culprit artery was treated during the
acute phase. The other arteries were treated secondarily by
PCI or bypass as a function of the ischemia test results.
TT was defined as the interval between symptom onset and
thrombolytic administration for patients treated by THL
and as the interval between symptom onset and balloon
deployment for patients treated by PPCI. Left ventricular
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ejection fraction was determined either with echocardio-
graphy or with angiography.
Statistical analysis
THL and PPCI were compared using Student's t-test (or Wil-
coxon's test, if necessary) and the chi2 test (or Fisher's exact
test if necessary). The analysis was conducted on the whole
population, then on the 3 age groups: [< 65 years]; [≤ 65 and
< 75 years]; [≥ 75 years]. Logistic regression models were
used to evaluate the association between 1-year mortality
and time to treatment. The analyses were stratified by rep-
erfusion type: THL or PPCI. The analyses were conducted on
the whole population and on the age subgroups. All the
analyses were conducted using the SAS 8.1 software (Cary,
NC).
Results
Characteristics of the patients on admission
and prognosis (table 1)
Out of the 1648 cases of STEMI between 1995 and 2005,
794 cases were included in the analysis. Of those patients,
495 were treated by PPCI and 299 by THL. The baseline
characteristics of the patients were similar except for the
significantly higher age in the PPCI group. The subgroup
analysis of the age groups did not show any significant dif-
ference. In the PPCI group, abciximab was used in 42% of
cases. Final angiographic success was obtained in 92.5%
of the cases. THL treatment was administered in pre-hos-
pital setting in 6.6 % of patients in this group. Rescue PCI
was implemented in 22.4% of cases. Control coronary
Figure 1. Population selection 
STEMI= ST elevation myocardial infarction; THL=thrombolysis; PPCI= Primary percutaneous coronary intervention.
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angiography was implemented in 96% of cases. The left
ventricular ejection fractions at discharge were similar for
the PPCI and THL groups. The 1-year mortality probability
was the same for the 2 treatment groups for the overall
population and for the patient subgroups aged [< 65 years];
[≥ 65 and < 75 years]. In contrast, the mortality was signifi-
cantly higher for the patient subgroup [≥ 75 years] treated
by THL.
Time to treatment study
The TT are shown in table 2. TT was significantly longer,
about 1 hour longer, in the PPCI group than in the THL
group (253 ± 133 vs. 191 ± 103 min, p = 0.0001). There was
not statistically significant difference neither for the
times to treatment of subgroups patients treated by PPCI
nor for the times to treatment of subgroups patients trea-
ted by THL.
Relationship between 1-year mortality, time
to treatment and reperfusion strategy
In the overall population, the 1-year mortality probability
was positively and continually dependent on the TT for both
treatment groups (figure 2). The logistic regression curves
show that up to age 65 years, THL is superior to PPCI if the
patients receive treatment within 2 hours of STEMI symp-
tom onset. After that interval, PPCI is superior to THL, irre-
spective of the TT (figure 3 a). In the group of patients aged
[≥ 65 and < 75 years], although there was no difference in
terms of mortality, PPCI seems superior to THL irrespective
of the TT (figure 3 b). From age 75 years, irrespective of
TT, PPCI is consistently superior to THL (figure 3 c).
Discussion
Unlike the results of recent data (4), this study suggests on
a 1-year mortality criteria that PPCI is not always upper
than THL in patients with STEMI. More particularly, the
study reminds the importance of TT and age on the results
of reperfusion algorithm.
Both reperfusion strategies are positively correlated with
TT but the results of PPCI are substantially less time to
treatment-dependent than those of THL (figure 2). For
PPCI, the plot is linear while it is exponential for THL (6).
Mechanisms other than myocardial rescue such as a
decrease in peri-infarct ischemia or a decrease in ventricu-
lar remodeling (7-9) may explain the benefit of late PPCI,
unless the benefit is, in fact, relative and related to the
inefficacy or negative effect of late THL (9). In addition,
the difference in the slopes of the mortality curves as a
function of TT indicates that the acceptable time to PPCI
Figure 2. Mortality as a function of time to treatment by reper-
fusion strategy 
Table 2 Times to admission and treatment by age group and reperfusion strategy
age (y)
overall < 65 y 65-74 y > 75 y
PPCI
N = 495 
THL
N = 299
PPCI
n=241
THL
n=181
PPCI
n=130
THL
n=83
PPCI
n=124
THL
n=35
Time from onset 
of symptoms 
to admission (min)
189 ± 121 164 ± 87* 179±129 158±76* 189±100 178±103 209±127 188±86
Time from onset 
of symptoms to start 
treatment (min)
253 ± 133 191 ± 103** 240±138 179±100** 253±111 201±98* 279±141 225±122*
Time from admission 
to angioplasty 
treatment (min)
65 ± 34 - 62±34 - 65±35 - 70±35 -
Time from admission 
to thrombolysis (min)
- 29 ± 44 - 30±36 - 26±43 - 38±75
The start of treatment was defined as the start of THL or the first balloon inflation. THL: thrombolysis; PCI: percutaneous coro-
nary intervention. Intervals are expressed as means ± SD *p < 0.05; **p < 0.001
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implementation is not fixed but depends on the time to
infarction management. For the same mortality probability,
the time to treatment difference: [PPCI time to treatment
- THL time to treatment] is variable. The later the patient
receives care, the greater the acceptable time to imple-
menting PPCI may be. That variability explains the diffi-
culty encountered in determining the optimum time inter-
val for PPCI implementation (PCI related delay = door to
balloon - door to needle). Depending on the study, this
delay ranges from 60 to 180 minutes (5, 10-12).
The logistic regression models for the patient subgroups
show that, for each reperfusion strategy, the effect of TT
on the 1-year mortality of STEMI patients varies greatly
depending on patient age. Thus, for patients aged up to
65 years, THL implemented within 2 hours of STEMI symp-
tom onset may be superior to PPCI. Subsequently, PPCI may
be superior to THL, even if the patient's door to balloon
interval is greater than 90 minutes. These results concord
with the PRAGUE 2 (13) and CAPTIM (14) data, for which the
patients were young (mean age: 58 years) and the TT was
particularly short (mean TT: 130 min). In patients aged ≥65
and < 75 years, although in the present study there was no
difference in 1-year mortality, the profile of the mortality
curves as a function of TT (figure 3b) are markedly different
from those for patients aged less than 65 years. PPCI still
seems to be a little superior to THL irrespective of the time
to THL. These findings are consistent with the results of the
DANAMI 2 study in which patients were older (mean age: 64
years) and the mean TT was much longer than in the CAPTIM
study (169 minutes).
From age 75 years, PPCI is significantly superior to THL
irrespective of the TT and including for STEMI treated very
early (figure 3c). In that subgroup, the 1-year mortality of
THL-treated patients was particularly marked, although the
treatment was administered by cardiologists who were very
conscious of the risk of such treatment. The prognosis of
STEMI patients would appear to be more related to the type
of reperfusion selected than to the TT (15-19). In that popu-
lation, the 'golden hour' concept was not evidenced. The
efficacy of THL could be compromised by a greater risk of
bleeding, cerebrovascular accident or free wall rupture
(20). Moreover, patient clinical risk profile of these patients
is completely different with markedly more women, fewer
smokers, more hypertension and more multi-vessels coro-
nary disease that could participate to explain the poor
benefit of THL in this subgroup. In those patients, it is even
possible that THL does not confer any survival benefit or
even worsens the prognosis, as has already been suggested
elsewhere (21-22).
The age subgroup analysis showed that age modifies the
impact of time to treatment on 1-year mortality for each
reperfusion strategy. In line with Pinto's findings (5), these
arguments are in favor of incorporating age in the reperfu-
sion algorithms, particularly since the datum is easy to
obtain.
While THL is undeniably pertinent up to 65 years and in
the first 2 hours post-STEMI symptom onset, further studies
are needed to determine its position in the management
algorithm for patients aged < 65 years after the two first
hours after symptoms onset or in patients aged between 65
and 75 years when PPCI is possible. This issue will continue
to be debated, particularly for as long as the results of
combined therapy studies are not positive (23). For patients
aged ≥ 75 years, THL should be used particularly carefully
Figure 3. Mortality curve as a function of time to treatment by reperfusion strategy 
Panel A: patients aged < 65 years; Panel B: patients aged ≥ 65 years and < 75 years; Panel C: patients aged ≥ 75 years.
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and the place of this treatment in this population needs to
be revalued.
The present study has inherent limits due to its registry
base. The small number of patients may be a limiting factor
for the analysis. This study has not a sufficient statistical
power to provide definite conclusion but aims to describe
the interaction between TT and age in revascularization
strategies. Patients were included over a long time period
during which the medicinal treatment of STEMI has evolved.
The fact that THL was mainly administered in the hospital
was not, however, a limitation, since the measurement unit
was the time to treatment and was thus independent of THL
administration site. 
Conclusion
TT and age remain two major parameters in reperfusion
algorithms. TT affects patient prognosis differently, depen-
ding on the reperfusion strategy implemented and the
patients' cardiovascular risk, particularly age. While it is
clear that THL is of value in the first 2 hours post-STEMI
symptom onset in patients aged up to 65 years, it might be
not appropriate after 75 years, irrespective of the time to
treatment. Furthermore, others studies are necessary to
specify the reperfusion algorithms in other cases of STEMI.
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